May 25, 2020

Unlearn.AI – $12 Million

Date posted: 04/22/2020

Business location: San Francisco, CA

Amount Funded: $12 Million

Type: Series A

Lead Investor: 8VC

Participating Investor(s):  DCVC, DCVC Bio, Mubadala Capital Ventures

Note:  Investors in red are new investors to this company.

Total Funding to Date: not listed

Company Description:  Unlearn has developed the first machine learning (ML) platform for creating Intelligent Control Arms with Digital Twins through its proprietary DiGenesisᵀᴹ process, allowing drug developers to dramatically improve clinical evidence and trial power, while lowering the risk of trial failure, thereby increasing confidence in clinical trial results. Unlearn is working closely with biopharmaceutical and medical device companies as well as regulators to ensure its methods meet the highest scientific and regulatory standards. 

What funding will be used for:  To accelerate Unlearn.AI’s machine learning to improve clinical trial efficiency and accuracy. 

Media/information contact:

Colin Sanford
colin@bioscribe.com
203.918.4347

Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy. 

 

StartupsOne

StartupsOne features relevant, focused news on venture capital funding of technology oriented startup businesses based in North America.

View all posts by StartupsOne →